Xencor, Inc. (NASDAQ:XNCR) Shares Bought by Braidwell LP

Braidwell LP raised its holdings in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 32.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 615,531 shares of the biopharmaceutical company's stock after buying an additional 149,083 shares during the period. Braidwell LP owned about 0.88% of Xencor worth $14,145,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Sterling Capital Management LLC grew its position in Xencor by 732.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 1,040 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 508 shares during the period. KBC Group NV grew its holdings in shares of Xencor by 26.0% in the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock worth $90,000 after purchasing an additional 813 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Xencor by 49.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock worth $93,000 after buying an additional 1,337 shares during the period. Finally, Summit Investment Advisors Inc. lifted its holdings in Xencor by 22.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company's stock valued at $162,000 after buying an additional 1,282 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on XNCR shares. Wells Fargo & Company decreased their price target on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Wedbush reissued an "outperform" rating and set a $31.00 price target on shares of Xencor in a research report on Wednesday, April 30th. William Blair assumed coverage on Xencor in a report on Monday, April 21st. They issued an "outperform" rating for the company. StockNews.com cut shares of Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Finally, Barclays reduced their price target on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a report on Thursday. Two research analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $29.50.

Insider Buying and Selling

In other news, EVP Nancy Valente sold 4,616 shares of the company's stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $11.03, for a total value of $50,914.48. Following the sale, the executive vice president now owns 49,169 shares in the company, valued at $542,334.07. This represents a 8.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.76% of the stock is owned by corporate insiders.

Xencor Stock Performance

Shares of NASDAQ XNCR traded down $0.46 during midday trading on Friday, reaching $8.33. The company had a trading volume of 935,748 shares, compared to its average volume of 641,132. The stock has a market cap of $592.70 million, a P/E ratio of -2.60 and a beta of 0.99. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a 1 year low of $7.16 and a 1 year high of $27.24. The business's 50-day simple moving average is $10.73 and its 200 day simple moving average is $17.63.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm had revenue of $32.73 million for the quarter, compared to analysts' expectations of $23.44 million. During the same quarter in the previous year, the firm posted ($1.11) EPS. The firm's revenue for the quarter was up 104.6% compared to the same quarter last year. On average, analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.